Descripción de la empresa
Annexon, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of therapeutic medicines designed to address inflammatory-related diseases. The company specifically focuses on advancing Tanruprubart, an investigational full-length monoclonal antibody currently undergoing Phase 3 clinical trials for the treatment of patients with Guillain-Barré syndrome. This organization functions within the broader Healthcare sector, specifically specializing in the Biotechnology industry, which implies a high degree of scientific innovation and regulatory scrutiny. Annexon, Inc. currently maintains a market capitalization of $961.24M and employs a workforce of 96 individuals. The market capitalization figure of $961.24M indicates that investors assign significant value to the company's pipeline assets despite the absence of reported annual revenue in the provided data, while the small employee count of 96 suggests a lean, asset-light operational model typical of early-to-mid stage biotechnology firms where capital is heavily allocated to research and development rather than large-scale commercial infrastructure.
Salud financiera
The financial statements for Annexon, Inc. reflect a net income (TTM) of $-208,547,008 and an EBITDA of $-214,240,992, with no reported revenue (TTM) available. The substantial gap between revenue (which is N/A) and the massive negative net income reveals a cost structure dominated by research and development expenses and clinical trial costs rather than commercial operating costs. Free cash flow stands at $-104,476,376, indicating that the company is burning cash to fund its development pipeline and lacks the immediate financial flexibility to cover operational outflows without external capital raises. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a figure that indicates the company has not yet achieved commercial revenue streams to generate a profit from sales or operations. On the balance sheet, the company holds $238.34M in cash against $26.20M in debt, resulting in a debt-to-equity ratio of 12.38. While the high debt-to-equity ratio technically suggests a leveraged position, the massive cash reserve relative to debt obligations implies a conservative liquidity stance regarding solvency. The current ratio is 5.68, which indicates a robust ability to meet short-term obligations with current assets, providing a strong buffer against immediate liquidity crises. Return on Equity is -81.9% and Return on Assets is -43.1%, metrics that reveal that management has not yet generated positive returns on shareholder capital or invested assets, a condition standard for clinical-stage companies but indicative of the high capital intensity required to progress their drug candidates.
Evaluación de valoración
The valuation metrics for Annexon, Inc. show a P/E Ratio (TTM) of N/A and a Forward P/E of -6.08. The negative forward P/E of -6.08 implies that the market expects earnings to remain negative in the near term, while the trailing P/E being N/A confirms the absence of profitable earnings history to benchmark against. The Price to Book ratio is 4.23, which indicates that the market values the company at more than four times its book value, suggesting a premium assigned to the potential value of the drug pipeline and intellectual property. The Price to Sales ratio is N/A and the EV/EBITDA is -3.50, suggesting that traditional revenue-based or earnings-based valuation multiples are not applicable due to the lack of commercial sales and negative earnings. The stock price has ranged between a 52-week low of $1.28 and a 52-week high of $7.18. Without the current price explicitly listed in the facts, the valuation is understood through these bounds, where the stock has demonstrated significant volatility within this specific range. The Beta is 1.15, meaning the stock exhibits price volatility that is 15% higher than the broader market, reflecting the elevated risk profile associated with biotechnology equities.
Growth & Income
The revenue growth (YoY) is listed as N/A and earnings growth (YoY) is also N/A, precluding a direct comparison of growth rates between earnings and revenue. Because the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%. The zero payout ratio confirms that the company retains all of its earnings—or in this case, absorbs its losses—reinvesting them directly into the research and development of its drug candidates rather than distributing income to shareholders. Since there are no dividends to pay, the 0.0% payout ratio is mathematically sustainable as the company prioritizes capital expenditure for clinical trials over shareholder distributions. The overall growth and income profile is characterized by a complete reliance on capital markets for funding due to the absence of commercial revenue, negative earnings growth, and a zero dividend yield, positioning the stock purely as a venture for future drug approval rather than a current income generator.